BioCentury | Jun 4, 2019
Distillery Therapeutics

RELMα and RETN for Gram-positive and Gram-negative bacterial infections

...P. acnes and other bacterial infections. TARGET/MARKER/PATHWAY: Resistin (RETN); resistin like α (RELMα; HIMF; FIZZ1...
...Lora V. Hooper, same affiliation as above email: lora.hooper@utsouthwestern.edu Mark Zipkin University of Texas Southwestern Medical Center Resistin (RETN) Resistin like alpha (RELMa) (HIMF) (FIZZ1) Streptococcus...
BioCentury | Oct 15, 2012
Finance

Pop, pop, fizz

Three new U.S. IPOs serve as a reminder there is no penalty for not investing in an early stage story that lacks near-term milestones - and investors know it. Intercept Pharmaceuticals Inc. and Kythera Biopharmaceuticals Inc....
BioCentury | Oct 15, 2012
Product Development

Gut instinct

Ardelyx Inc. took its gut-specific small molecule approach from concept to Phase II testing in under four years and now has scored a partnership with AstraZeneca plc as the pharma adds diabetic complications as a...
BioCentury | Oct 15, 2012
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Celgene Corp. (NASDAQ:CELG) was up $0.70 to $78.42 on Friday after FDA approved an sNDA for Abraxane nab-paclitaxel for first-line treatment of advanced non-small cell lung cancer (NSCLC). The product was first approved...
BioCentury | Apr 30, 2009
Distillery Therapeutics

Indication: Inflammation

...in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Inflammation Inflammation Resistin-like-α (HIMF...
BioCentury | May 19, 2008
Finance

Ebb & Flow

Making good on plans to expand its footprint in Asia, MPM Capital made a $20 million investment in Hyderabad CRO Sai Avantium last week. The company's primary focus is on providing chemistry services to biotech...
BioCentury | Aug 13, 2007
Product Development

Faster followers in pain

When Cephalon Inc. bought Anesta Corp. in 2000 for $444 million in stock, the main driver of the deal was Actiq transmucosal fentanyl for breakthrough cancer pain. The acquisition didn't take long to pay dividends,...
BioCentury | Jan 10, 2000
Finance

Spreading the wealth

Buyside Europe Spreading the wealth OXFORD - Not everyone is entirely happy with the current U.S. biotech fizz. Anthony Milford of Framlington Health Fund in London prefers to invest in biotech stocks when they are both...
Items per page:
1 - 8 of 8